Hengrui Pharma (01276) Completes Cumulative Share Buyback of 9.0737 Million Shares by January 27

Stock News01-27

Hengrui Pharma (01276) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "Company") held its 18th meeting of the 9th Board of Directors on August 20, 2025, where a proposal to repurchase the Company's A-shares via centralized bidding was reviewed and approved. The proposal authorized the Company to use its own funds to repurchase shares through centralized bidding transactions, intended for an A-share employee stock ownership plan.

The repurchase price is set not to exceed RMB 90.85 per share (inclusive), with a total repurchase amount of no less than RMB 1 billion and no more than RMB 2 billion. The repurchase period is within 12 months from the date the board approved the share repurchase proposal.

In January 2026, the Company repurchased 175,000 shares via the Shanghai Stock Exchange trading system using the centralized bidding method. These repurchased shares account for 0.003% of the Company's total share capital, with the highest purchase price at RMB 57.48 per share and the lowest at RMB 57.20 per share. The total amount paid was RMB 10.0386 million (excluding transaction fees).

As of January 27, 2026, the Company had cumulatively repurchased 9.0737 million shares under this buyback program through the Shanghai Stock Exchange trading system via centralized bidding. The cumulative repurchased shares represent 0.14% of the total share capital, with the highest purchase price at RMB 70.00 per share and the lowest at RMB 57.20 per share. The total amount paid has reached RMB 605 million (excluding transaction fees).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147661680?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 17:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147661680","market":"other","top_or_hot":-1,"title":"Hengrui Pharma (01276) Completes Cumulative Share Buyback of 9.0737 Million Shares by January 27","media":"Stock News","content":"<p>Hengrui Pharma (01276) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the \"Company\") held its 18th meeting of the 9th Board of Directors on August 20, 2025, where a proposal to repurchase the Company's A-shares via centralized bidding was reviewed and approved. The proposal authorized the Company to use its own funds to repurchase shares through centralized bidding transactions, intended for an A-share employee stock ownership plan.</p>\n<p>The repurchase price is set not to exceed RMB 90.85 per share (inclusive), with a total repurchase amount of no less than RMB 1 billion and no more than RMB 2 billion. The repurchase period is within 12 months from the date the board approved the share repurchase proposal.</p>\n<p>In January 2026, the Company repurchased 175,000 shares via the Shanghai Stock Exchange trading system using the centralized bidding method. These repurchased shares account for 0.003% of the Company's total share capital, with the highest purchase price at RMB 57.48 per share and the lowest at RMB 57.20 per share. The total amount paid was RMB 10.0386 million (excluding transaction fees).</p>\n<p>As of January 27, 2026, the Company had cumulatively repurchased 9.0737 million shares under this buyback program through the Shanghai Stock Exchange trading system via centralized bidding. The cumulative repurchased shares represent 0.14% of the total share capital, with the highest purchase price at RMB 70.00 per share and the lowest at RMB 57.20 per share. The total amount paid has reached RMB 605 million (excluding transaction fees).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Pharma (01276) Completes Cumulative Share Buyback of 9.0737 Million Shares by January 27</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Pharma (01276) Completes Cumulative Share Buyback of 9.0737 Million Shares by January 27\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-27 17:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hengrui Pharma (01276) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the \"Company\") held its 18th meeting of the 9th Board of Directors on August 20, 2025, where a proposal to repurchase the Company's A-shares via centralized bidding was reviewed and approved. The proposal authorized the Company to use its own funds to repurchase shares through centralized bidding transactions, intended for an A-share employee stock ownership plan.</p>\n<p>The repurchase price is set not to exceed RMB 90.85 per share (inclusive), with a total repurchase amount of no less than RMB 1 billion and no more than RMB 2 billion. The repurchase period is within 12 months from the date the board approved the share repurchase proposal.</p>\n<p>In January 2026, the Company repurchased 175,000 shares via the Shanghai Stock Exchange trading system using the centralized bidding method. These repurchased shares account for 0.003% of the Company's total share capital, with the highest purchase price at RMB 57.48 per share and the lowest at RMB 57.20 per share. The total amount paid was RMB 10.0386 million (excluding transaction fees).</p>\n<p>As of January 27, 2026, the Company had cumulatively repurchased 9.0737 million shares under this buyback program through the Shanghai Stock Exchange trading system via centralized bidding. The cumulative repurchased shares represent 0.14% of the total share capital, with the highest purchase price at RMB 70.00 per share and the lowest at RMB 57.20 per share. The total amount paid has reached RMB 605 million (excluding transaction fees).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1147661680","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147661680","pubTimestamp":1769507552,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hengrui Pharma (01276) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the \"Company\") held its 18th meeting of the 9th Board of Directors on August 20, 2025, where a proposal to repurchase...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","BK0196":"行业龙头","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","01276":"恒瑞医药","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK0239":"医药制造","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0183":"MSCI概念","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0188":"融资融券","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BK0012":"证金概念","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU0359201612.USD":"贝莱德中国基金A2","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","BK0028":"国家队","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK1191":"制药","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK0060":"抗癌","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC"},"translate_title":"恒瑞医药(01276)截至1月27日累计完成股份回购907.37万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"01276":1},"content_text":"Hengrui Pharma (01276) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the \"Company\") held its 18th meeting of the 9th Board of Directors on August 20, 2025, where a proposal to repurchase the Company's A-shares via centralized bidding was reviewed and approved. The proposal authorized the Company to use its own funds to repurchase shares through centralized bidding transactions, intended for an A-share employee stock ownership plan.\nThe repurchase price is set not to exceed RMB 90.85 per share (inclusive), with a total repurchase amount of no less than RMB 1 billion and no more than RMB 2 billion. The repurchase period is within 12 months from the date the board approved the share repurchase proposal.\nIn January 2026, the Company repurchased 175,000 shares via the Shanghai Stock Exchange trading system using the centralized bidding method. These repurchased shares account for 0.003% of the Company's total share capital, with the highest purchase price at RMB 57.48 per share and the lowest at RMB 57.20 per share. The total amount paid was RMB 10.0386 million (excluding transaction fees).\nAs of January 27, 2026, the Company had cumulatively repurchased 9.0737 million shares under this buyback program through the Shanghai Stock Exchange trading system via centralized bidding. The cumulative repurchased shares represent 0.14% of the total share capital, with the highest purchase price at RMB 70.00 per share and the lowest at RMB 57.20 per share. The total amount paid has reached RMB 605 million (excluding transaction fees).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147661680","isCrawlerRequest":true}